drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB06691 | DB06700 | 849 | 643 | [
"DDInter1155",
"DDInter511"
] | Mepyramine | Desvenlafaxine | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Moderate | 1 | [
[
[
849,
24,
643
]
],
[
[
849,
63,
1100
],
[
1100,
1,
643
]
],
[
[
849,
63,
1311
],
[
1311,
24,
643
]
],
[
[
849,
24,
407
],
[
407,
... | [
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
... | Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interact... |
DB00790 | DB01309 | 664 | 1,254 | [
"DDInter1431",
"DDInter933"
] | Perindopril | Insulin glulisine | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
664,
24,
1254
]
],
[
[
664,
64,
1621
],
[
1621,
23,
1254
]
],
[
[
664,
25,
948
],
[
948,
62,
1254
]
],
[
[
664,
63,
167
],
[
167,
... | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Perindopril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
... | Perindopril may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine
Perindopril may lead to a major life threatening interaction when taken with Potassium gluconate and Pota... |
DB04845 | DB11793 | 309 | 738 | [
"DDInter1001",
"DDInter1297"
] | Ixabepilone | Niraparib | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
309,
24,
738
]
],
[
[
309,
63,
1213
],
[
1213,
24,
738
]
],
[
[
309,
24,
496
],
[
496,
24,
738
]
],
[
[
309,
24,
1619
],
[
1619,
... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine an... |
DB00851 | DB06643 | 611 | 1,136 | [
"DDInter463",
"DDInter500"
] | Dacarbazine | Denosumab | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
611,
24,
1136
]
],
[
[
611,
63,
1555
],
[
1555,
24,
1136
]
],
[
[
611,
64,
1648
],
[
1648,
24,
1136
]
],
[
[
611,
24,
1532
],
[
1532,
... | [
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
... | Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Dacarbazine may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may c... |
DB00176 | DB12267 | 529 | 1,476 | [
"DDInter770",
"DDInter233"
] | Fluvoxamine | Brigatinib | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
529,
24,
1476
]
],
[
[
529,
23,
1135
],
[
1135,
23,
1476
]
],
[
[
529,
24,
629
],
[
629,
24,
1476
]
],
[
[
529,
63,
176
],
[
176,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Fluvoxamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus m... |
DB00224 | DB06616 | 215 | 594 | [
"DDInter917",
"DDInter224"
] | Indinavir | Bosutinib | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Major | 2 | [
[
[
215,
25,
594
]
],
[
[
215,
24,
883
],
[
883,
1,
594
]
],
[
[
215,
6,
8374
],
[
8374,
45,
594
]
],
[
[
215,
7,
4786
],
[
4786,
45... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
... | Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)
Indinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Indinavir (Compound) upregulates EPHB2 (Gene) and EPHB2 (Gene) is bound ... |
DB00598 | DB08938 | 1,523 | 1,384 | [
"DDInter1013",
"DDInter1112"
] | Labetalol | Magaldrate | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Minor | 0 | [
[
[
1523,
23,
1384
]
],
[
[
1523,
24,
167
],
[
167,
23,
1384
]
],
[
[
1523,
63,
752
],
[
752,
23,
1384
]
],
[
[
1523,
40,
954
],
[
954,
... | [
[
[
"Labetalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
... | Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Ci... |
DB00321 | DB08897 | 21 | 1,429 | [
"DDInter78",
"DDInter22"
] | Amitriptyline | Aclidinium | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. | Moderate | 1 | [
[
[
21,
24,
1429
]
],
[
[
21,
63,
352
],
[
352,
24,
1429
]
],
[
[
21,
24,
1511
],
[
1511,
24,
1429
]
],
[
[
21,
6,
4304
],
[
4304,
4... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
... | Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mep... |
DB00295 | DB00754 | 475 | 157 | [
"DDInter1244",
"DDInter696"
] | Morphine | Ethotoin | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Moderate | 1 | [
[
[
475,
24,
157
]
],
[
[
475,
25,
759
],
[
759,
40,
157
]
],
[
[
475,
24,
499
],
[
499,
1,
157
]
],
[
[
475,
21,
28763
],
[
28763,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primidone"
],
[
"Primidone",
... | Morphine may lead to a major life threatening interaction when taken with Primidone and Primidone (Compound) resembles Ethotoin (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Phensuximide and Phensuximide (Compound) resembles Ethotoin (Compound)
Morphine (Compound) c... |
DB04845 | DB11730 | 309 | 351 | [
"DDInter1001",
"DDInter1588"
] | Ixabepilone | Ribociclib | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
309,
24,
351
]
],
[
[
309,
63,
112
],
[
112,
23,
351
]
],
[
[
309,
24,
283
],
[
283,
62,
351
]
],
[
[
309,
24,
861
],
[
861,
63,... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and ... |
DB01142 | DB04855 | 1,264 | 540 | [
"DDInter593",
"DDInter602"
] | Doxepin | Dronedarone | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Major | 2 | [
[
[
1264,
25,
540
]
],
[
[
1264,
64,
347
],
[
347,
40,
540
]
],
[
[
1264,
6,
8195
],
[
8195,
45,
540
]
],
[
[
1264,
21,
28883
],
[
28883,
... | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibutilide"
],
[
"Ibutilide",
"{u} (Compoun... | Doxepin may lead to a major life threatening interaction when taken with Ibutilide and Ibutilide (Compound) resembles Dronedarone (Compound)
Doxepin (Compound) binds ADRA2B (Gene) and ADRA2B (Gene) is bound by Dronedarone (Compound)
Doxepin (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) i... |
DB00295 | DB00850 | 475 | 1,630 | [
"DDInter1244",
"DDInter1432"
] | Morphine | Perphenazine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Major | 2 | [
[
[
475,
25,
1630
]
],
[
[
475,
25,
252
],
[
252,
40,
1630
]
],
[
[
475,
24,
827
],
[
827,
40,
1630
]
],
[
[
475,
24,
1242
],
[
1242,
... | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Perphenazine"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} (... | Morphine may lead to a major life threatening interaction when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Perphenazine (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Perphenazine (Compound)
Morphine may ca... |
DB00860 | DB09564 | 891 | 1,296 | [
"DDInter1513",
"DDInter930"
] | Prednisolone | Insulin degludec | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
891,
24,
1296
]
],
[
[
891,
40,
1103
],
[
1103,
23,
1296
]
],
[
[
891,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
891,
23,
659
],
[
659,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause... | Prednisolone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction ... |
DB00451 | DB06655 | 542 | 5 | [
"DDInter1064",
"DDInter1077"
] | Levothyroxine | Liraglutide | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
542,
24,
5
]
],
[
[
542,
63,
1252
],
[
1252,
23,
5
]
],
[
[
542,
24,
1142
],
[
1142,
24,
5
]
],
[
[
542,
24,
192
],
[
192,
63,
... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
... | Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlistat ... |
DB01320 | DB08899 | 651 | 129 | [
"DDInter783",
"DDInter649"
] | Fosphenytoin | Enzalutamide | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
651,
24,
129
]
],
[
[
651,
6,
8374
],
[
8374,
45,
129
]
],
[
[
651,
21,
28703
],
[
28703,
60,
129
]
],
[
[
651,
63,
112
],
[
112,
... | [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Fosphenytoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Fosphenytoin (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazo... |
DB00215 | DB00902 | 1,230 | 104 | [
"DDInter388",
"DDInter1168"
] | Citalopram | Methdilazine | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
1230,
24,
104
]
],
[
[
1230,
24,
13
],
[
13,
24,
104
]
],
[
[
1230,
25,
820
],
[
820,
1,
104
]
],
[
[
1230,
24,
537
],
[
537,
40... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
... | Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Citalopram may lead to a major life threatening interaction when taken with Alimemazine and Alimemazin... |
DB11003 | DB11714 | 748 | 1,316 | [
"DDInter100",
"DDInter610"
] | Anthrax vaccine | Durvalumab | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote... | Moderate | 1 | [
[
[
748,
24,
1316
]
],
[
[
748,
63,
167
],
[
167,
24,
1316
]
],
[
[
748,
24,
270
],
[
270,
63,
1316
]
],
[
[
748,
63,
976
],
[
976,
... | [
[
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Durvalumab"
]
],
[
[
"Anthrax vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
... | Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Ocr... |
DB00387 | DB01409 | 1,386 | 1,415 | [
"DDInter1528",
"DDInter1815"
] | Procyclidine | Tiotropium | A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L... | Moderate | 1 | [
[
[
1386,
24,
1415
]
],
[
[
1386,
6,
4304
],
[
4304,
45,
1415
]
],
[
[
1386,
63,
1594
],
[
1594,
24,
1415
]
],
[
[
1386,
24,
1219
],
[
121... | [
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Procyclidine",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)... | Procyclidine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Tiotropium (Compound)
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Procyclidine may... |
DB00370 | DB08912 | 1,251 | 1,040 | [
"DDInter1230",
"DDInter462"
] | Mirtazapine | Dabrafenib | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1251,
24,
1040
]
],
[
[
1251,
6,
3486
],
[
3486,
45,
1040
]
],
[
[
1251,
18,
10699
],
[
10699,
57,
1040
]
],
[
[
1251,
21,
28900
],
[
... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Mirtazapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)... | Mirtazapine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Dabrafenib (Compound)
Mirtazapine (Compound) downregulates KIF20A (Gene) and KIF20A (Gene) is downregulated by Dabrafenib (Compound)
Mirtazapine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafeni... |
DB00544 | DB14444 | 970 | 151 | [
"DDInter757",
"DDInter924"
] | Fluorouracil | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
970,
24,
151
]
],
[
[
970,
63,
66
],
[
66,
24,
151
]
],
[
[
970,
24,
869
],
[
869,
24,
151
]
],
[
[
970,
25,
375
],
[
375,
24,
... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that cou... | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Fluorouracil may cause a moderate i... |
DB00432 | DB11817 | 1,083 | 1,259 | [
"DDInter1868",
"DDInter165"
] | Trifluridine | Baricitinib | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
1083,
25,
1259
]
],
[
[
1083,
63,
1461
],
[
1461,
23,
1259
]
],
[
[
1083,
24,
949
],
[
949,
24,
1259
]
],
[
[
1083,
24,
1129
],
[
1129... | [
[
[
"Trifluridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitami... | Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani t... |
DB04868 | DB11901 | 478 | 913 | [
"DDInter1293",
"DDInter107"
] | Nilotinib | Apalutamide | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
478,
25,
913
]
],
[
[
478,
62,
112
],
[
112,
23,
913
]
],
[
[
478,
23,
271
],
[
271,
23,
913
]
],
[
[
478,
24,
110
],
[
110,
62,... | [
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Nilotinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabeg... |
DB01362 | DB01618 | 497 | 776 | [
"DDInter960",
"DDInter1239"
] | Iohexol | Molindone | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Major | 2 | [
[
[
497,
25,
776
]
],
[
[
497,
21,
28680
],
[
28680,
60,
776
]
],
[
[
497,
64,
1532
],
[
1532,
24,
776
]
],
[
[
497,
25,
407
],
[
407,
... | [
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Molindone"
]
],
[
[
"Iohexol",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mo... | Iohexol (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Molindone (Compound)
Iohexol may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Molindone
Iohexol may lead to a major l... |
DB00039 | DB00851 | 1,253 | 611 | [
"DDInter1380",
"DDInter463"
] | Palifermin | Dacarbazine | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Moderate | 1 | [
[
[
1253,
24,
611
]
],
[
[
1253,
24,
141
],
[
141,
24,
611
]
],
[
[
1253,
24,
850
],
[
850,
63,
611
]
],
[
[
1253,
24,
1648
],
[
1648,
... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Floxuridine"
],
[
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedoti... |
DB09036 | DB12674 | 812 | 975 | [
"DDInter1668",
"DDInter1105"
] | Siltuximab | Lurbinectedin | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
812,
24,
975
]
],
[
[
812,
63,
147
],
[
147,
24,
975
]
],
[
[
812,
24,
270
],
[
270,
24,
975
]
],
[
[
812,
25,
1259
],
[
1259,
2... | [
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
... | Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and ... |
DB00622 | DB12130 | 1,081 | 1,017 | [
"DDInter1287",
"DDInter1094"
] | Nicardipine | Lorlatinib | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1081,
24,
1017
]
],
[
[
1081,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
1081,
63,
175
],
[
175,
24,
1017
]
],
[
[
1081,
40,
409
],
[
409,
... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Tri... |
DB00214 | DB00618 | 1,028 | 1,572 | [
"DDInter1836",
"DDInter498"
] | Torasemide | Demeclocycline | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Minor | 0 | [
[
[
1028,
23,
1572
]
],
[
[
1028,
23,
1620
],
[
1620,
1,
1572
]
],
[
[
1028,
23,
1669
],
[
1669,
40,
1572
]
],
[
[
1028,
24,
286
],
[
286,... | [
[
[
"Torasemide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Demeclocycline"
]
],
[
[
"Torasemide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracycline"
],
[
... | Torasemide may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline (Compound) resembles Demeclocycline (Compound)
Torasemide may cause a minor interaction that can limit clinical effects when taken with Minocycline and Minocycline (Compound) resembles Demeclocycline (... |
DB09104 | DB11730 | 286 | 351 | [
"DDInter1118",
"DDInter1588"
] | Magnesium hydroxide | Ribociclib | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
286,
24,
351
]
],
[
[
286,
62,
355
],
[
355,
24,
351
]
],
[
[
286,
63,
1486
],
[
1486,
24,
351
]
],
[
[
286,
24,
255
],
[
255,
6... | [
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lactulose"
... | Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Methylp... |
DB00514 | DB08883 | 506 | 1,597 | [
"DDInter527",
"DDInter1428"
] | Dextromethorphan | Perampanel | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning ... | Moderate | 1 | [
[
[
506,
24,
1597
]
],
[
[
506,
24,
100
],
[
100,
24,
1597
]
],
[
[
506,
63,
128
],
[
128,
24,
1597
]
],
[
[
506,
24,
407
],
[
407,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perampanel"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Perampanel
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00188 | DB00570 | 168 | 147 | [
"DDInter222",
"DDInter1936"
] | Bortezomib | Vinblastine | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Moderate | 1 | [
[
[
168,
24,
147
]
],
[
[
168,
24,
134
],
[
134,
24,
147
]
],
[
[
168,
5,
11555
],
[
11555,
44,
147
]
],
[
[
168,
6,
8374
],
[
8374,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Bortezomib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Vinb... |
DB00701 | DB09030 | 1,091 | 840 | [
"DDInter90",
"DDInter1945"
] | Amprenavir | Vorapaxar | Amprenavir is a protease inhibitor used to treat HIV infection. | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
1091,
25,
840
]
],
[
[
1091,
24,
1017
],
[
1017,
63,
840
]
],
[
[
1091,
24,
578
],
[
578,
24,
840
]
],
[
[
1091,
25,
159
],
[
159,
... | [
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib"... | Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagre... |
DB00983 | DB06204 | 480 | 768 | [
"DDInter776",
"DDInter1746"
] | Formoterol | Tapentadol | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Moderate | 1 | [
[
[
480,
24,
768
]
],
[
[
480,
6,
10215
],
[
10215,
45,
768
]
],
[
[
480,
21,
28692
],
[
28692,
60,
768
]
],
[
[
480,
24,
1148
],
[
1148,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Formoterol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)... | Formoterol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tapentadol (Compound)
Formoterol (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Tapentadol (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isopr... |
DB00687 | DB06723 | 870 | 115 | [
"DDInter747",
"DDInter58"
] | Fludrocortisone | Aluminum hydroxide | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Minor | 0 | [
[
[
870,
23,
115
]
],
[
[
870,
21,
28643
],
[
28643,
60,
115
]
],
[
[
870,
24,
1058
],
[
1058,
23,
115
]
],
[
[
870,
63,
1252
],
[
1252,
... | [
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side... | Fludrocortisone (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Aluminum hydroxide (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Moexipril and Moexipril may cause a minor interaction that can limit clinical effects when take... |
DB00790 | DB06822 | 664 | 802 | [
"DDInter1431",
"DDInter1812"
] | Perindopril | Tinzaparin | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Moderate | 1 | [
[
[
664,
24,
802
]
],
[
[
664,
40,
1058
],
[
1058,
24,
802
]
],
[
[
664,
63,
305
],
[
305,
24,
802
]
],
[
[
664,
1,
954
],
[
954,
24... | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinzaparin"
]
],
[
[
"Perindopril",
"{u} (Compound) resembles {v} (Compound)",
"Moexipril"
],
[
"Moexipril",
"{u} may cause a moderat... | Perindopril (Compound) resembles Moexipril (Compound) and Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may c... |
DB08916 | DB14840 | 26 | 861 | [
"DDInter32",
"DDInter1601"
] | Afatinib | Ripretinib | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal grow... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
26,
24,
861
]
],
[
[
26,
24,
351
],
[
351,
24,
861
]
],
[
[
26,
63,
392
],
[
392,
24,
861
]
],
[
[
26,
74,
1069
],
[
1069,
24,
... | [
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib m... |
DB00468 | DB00674 | 1,424 | 1,516 | [
"DDInter1557",
"DDInter802"
] | Quinine | Galantamine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Moderate | 1 | [
[
[
1424,
24,
1516
]
],
[
[
1424,
6,
8374
],
[
8374,
45,
1516
]
],
[
[
1424,
21,
28766
],
[
28766,
60,
1516
]
],
[
[
1424,
63,
618
],
[
61... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Galantamine"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Quinine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Galantamine (Compound)
Quinine (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Galantamine (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix ... |
DB00344 | DB06699 | 1,302 | 774 | [
"DDInter1543",
"DDInter493"
] | Protriptyline | Degarelix | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
1302,
24,
774
]
],
[
[
1302,
63,
521
],
[
521,
1,
774
]
],
[
[
1302,
21,
29232
],
[
29232,
60,
774
]
],
[
[
1302,
23,
112
],
[
112,
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
... | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Protriptyline (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Protriptyline may cause a minor interactio... |
DB00804 | DB01618 | 1,507 | 776 | [
"DDInter543",
"DDInter1239"
] | Dicyclomine | Molindone | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Moderate | 1 | [
[
[
1507,
24,
776
]
],
[
[
1507,
6,
7992
],
[
7992,
45,
776
]
],
[
[
1507,
21,
28800
],
[
28800,
60,
776
]
],
[
[
1507,
24,
100
],
[
100,
... | [
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Molindone"
]
],
[
[
"Dicyclomine",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compound)",
... | Dicyclomine (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Molindone (Compound)
Dicyclomine (Compound) causes Dyskinesia (Side Effect) and Dyskinesia (Side Effect) is caused by Molindone (Compound)
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine an... |
DB01168 | DB01577 | 1,053 | 1,529 | [
"DDInter1526",
"DDInter1161"
] | Procarbazine | Metamfetamine | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potentia... | Major | 2 | [
[
[
1053,
25,
1529
]
],
[
[
1053,
64,
939
],
[
939,
40,
1529
]
],
[
[
1053,
25,
93
],
[
93,
1,
1529
]
],
[
[
1053,
25,
22
],
[
22,
2... | [
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metamfetamine"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Benzphetamine"
],
[
"Benzphetamine",... | Procarbazine may lead to a major life threatening interaction when taken with Benzphetamine and Benzphetamine (Compound) resembles Metamfetamine (Compound)
Procarbazine may lead to a major life threatening interaction when taken with Dextroamphetamine and Dextroamphetamine (Compound) resembles Metamfetamine (Compound)
... |
DB00215 | DB11095 | 1,230 | 235 | [
"DDInter388",
"DDInter505"
] | Citalopram | Desirudin | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three dis... | Moderate | 1 | [
[
[
1230,
24,
235
]
],
[
[
1230,
25,
1151
],
[
1151,
24,
235
]
],
[
[
1230,
24,
578
],
[
578,
24,
235
]
],
[
[
1230,
1,
318
],
[
318,
... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
... | Citalopram may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a m... |
DB00081 | DB15233 | 273 | 1,650 | [
"DDInter1838",
"DDInter142"
] | Tositumomab | Avapritinib | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
273,
25,
1650
]
],
[
[
273,
63,
1257
],
[
1257,
24,
1650
]
],
[
[
273,
24,
58
],
[
58,
24,
1650
]
],
[
[
273,
25,
908
],
[
908,
... | [
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegfilgrastim"
],
[
"Pegf... | Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim and Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept an... |
DB00294 | DB00357 | 1,336 | 1,051 | [
"DDInter701",
"DDInter71"
] | Etonogestrel | Aminoglutethimide | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Moderate | 1 | [
[
[
1336,
24,
1051
]
],
[
[
1336,
6,
8374
],
[
8374,
45,
1051
]
],
[
[
1336,
21,
28681
],
[
28681,
60,
1051
]
],
[
[
1336,
24,
1411
],
[
1... | [
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
]
],
[
[
"Etonogestrel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (... | Etonogestrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aminoglutethimide (Compound)
Etonogestrel (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Aminoglutethimide (Compound)
Etonogestrel may cause a moderate interaction that could exacerbate diseases w... |
DB01583 | DB01592 | 624 | 1,596 | [
"DDInter1075",
"DDInter975"
] | Liotrix | Iron | Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal s... | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletio... | Moderate | 1 | [
[
[
624,
24,
1596
]
],
[
[
624,
21,
29243
],
[
29243,
60,
1596
]
],
[
[
624,
63,
1215
],
[
1215,
24,
1596
]
],
[
[
624,
24,
1384
],
[
1384... | [
[
[
"Liotrix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Liotrix",
"{u} (Compound) causes {v} (Side Effect)",
"Wheezing"
],
[
"Wheezing",
"{u} (Side Effect) is caused by {v} (Com... | Liotrix (Compound) causes Wheezing (Side Effect) and Wheezing (Side Effect) is caused by Iron (Compound)
Liotrix may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Iron
Liotrix may ... |
DB01320 | DB09570 | 651 | 1,480 | [
"DDInter783",
"DDInter1002"
] | Fosphenytoin | Ixazomib | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Major | 2 | [
[
[
651,
25,
1480
]
],
[
[
651,
24,
310
],
[
310,
24,
1480
]
],
[
[
651,
63,
1184
],
[
1184,
24,
1480
]
],
[
[
651,
40,
998
],
[
998,
... | [
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazit... | Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anak... |
DB00881 | DB01069 | 954 | 401 | [
"DDInter1554",
"DDInter1533"
] | Quinapril | Promethazine | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
954,
24,
401
]
],
[
[
954,
24,
1264
],
[
1264,
63,
401
]
],
[
[
954,
24,
104
],
[
104,
24,
401
]
],
[
[
954,
21,
28787
],
[
28787,
... | [
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazi... |
DB00263 | DB09112 | 1,029 | 1,455 | [
"DDInter1727",
"DDInter1306"
] | Sulfisoxazole | Nitrous acid | A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Major | 2 | [
[
[
1029,
25,
1455
]
],
[
[
1029,
40,
161
],
[
161,
25,
1455
]
],
[
[
1029,
1,
1247
],
[
1247,
25,
1455
]
],
[
[
1029,
74,
10
],
[
10,
... | [
[
[
"Sulfisoxazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
]
],
[
[
"Sulfisoxazole",
"{u} (Compound) resembles {v} (Compound)",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may lead to a major li... | Sulfisoxazole (Compound) resembles Sulfadiazine (Compound) and Sulfadiazine may lead to a major life threatening interaction when taken with Nitrous acid
Sulfisoxazole (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may lead to a major life threatening interaction when taken with Nitrous acid
Sulf... |
DB01036 | DB09065 | 211 | 760 | [
"DDInter1832",
"DDInter424"
] | Tolterodine | Cobicistat | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
211,
24,
760
]
],
[
[
211,
23,
1374
],
[
1374,
23,
760
]
],
[
[
211,
63,
723
],
[
723,
24,
760
]
],
[
[
211,
23,
868
],
[
868,
2... | [
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Tolterodine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
],
[
... | Tolterodine may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepi... |
DB00186 | DB00662 | 905 | 717 | [
"DDInter1092",
"DDInter1873"
] | Lorazepam | Trimethobenzamide | Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm. | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Moderate | 1 | [
[
[
905,
24,
717
]
],
[
[
905,
21,
29648
],
[
29648,
60,
717
]
],
[
[
905,
40,
1382
],
[
1382,
63,
717
]
],
[
[
905,
40,
695
],
[
695,
... | [
[
[
"Lorazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Lorazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Disorientation"
],
[
"Disorientation",
"{u} (Side ... | Lorazepam (Compound) causes Disorientation (Side Effect) and Disorientation (Side Effect) is caused by Trimethobenzamide (Compound)
Lorazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Lorazepam (Compound) res... |
DB00679 | DB11963 | 684 | 1,045 | [
"DDInter1796",
"DDInter465"
] | Thioridazine | Dacomitinib | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was devel... | Major | 2 | [
[
[
684,
25,
1045
]
],
[
[
684,
25,
1039
],
[
1039,
24,
1045
]
],
[
[
684,
24,
272
],
[
272,
24,
1045
]
],
[
[
684,
40,
1630
],
[
1630,
... | [
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacomitinib"
]
],
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine... | Thioridazine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and ... |
DB01403 | DB09045 | 9 | 52 | [
"DDInter1175",
"DDInter607"
] | Methotrimeprazine | Dulaglutide | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
9,
24,
52
]
],
[
[
9,
63,
170
],
[
170,
23,
52
]
],
[
[
9,
63,
609
],
[
609,
24,
52
]
],
[
[
9,
25,
1154
],
[
1154,
24,
52... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"... | Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Clarit... |
DB00603 | DB06655 | 303 | 5 | [
"DDInter1137",
"DDInter1077"
] | Medroxyprogesterone acetate | Liraglutide | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
303,
24,
5
]
],
[
[
303,
64,
353
],
[
353,
23,
5
]
],
[
[
303,
23,
700
],
[
700,
23,
5
]
],
[
[
303,
24,
915
],
[
915,
24,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Griseof... | Medroxyprogesterone acetate may lead to a major life threatening interaction when taken with Griseofulvin and Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken with A... |
DB08886 | DB08901 | 637 | 1,468 | [
"DDInter126",
"DDInter1492"
] | Asparaginase Erwinia chrysanthemi | Ponatinib | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
637,
24,
1468
]
],
[
[
637,
63,
478
],
[
478,
24,
1468
]
],
[
[
637,
24,
384
],
[
384,
63,
1468
]
],
[
[
637,
24,
350
],
[
350,
... | [
[
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when taken ... | Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate dis... |
DB00434 | DB01202 | 13 | 1,435 | [
"DDInter459",
"DDInter1046"
] | Cyproheptadine | Levetiracetam | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam poss... | Moderate | 1 | [
[
[
13,
24,
1435
]
],
[
[
13,
7,
15515
],
[
15515,
46,
1435
]
],
[
[
13,
21,
28769
],
[
28769,
60,
1435
]
],
[
[
13,
63,
701
],
[
701,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levetiracetam"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) upregulates {v} (Gene)",
"ADO"
],
[
"ADO",
"{u} (Gene) is upregulated by... | Cyproheptadine (Compound) upregulates ADO (Gene) and ADO (Gene) is upregulated by Levetiracetam (Compound)
Cyproheptadine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Levetiracetam (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseas... |
DB09073 | DB14711 | 951 | 779 | [
"DDInter1379",
"DDInter1680"
] | Palbociclib | Smallpox (Vaccinia) Vaccine, Live | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
951,
25,
779
]
],
[
[
951,
64,
1064
],
[
1064,
25,
779
]
],
[
[
951,
63,
478
],
[
478,
25,
779
]
],
[
[
951,
25,
1259
],
[
1259,
... | [
[
[
"Palbociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Palbociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"... | Palbociclib may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib ma... |
DB00308 | DB11113 | 347 | 657 | [
"DDInter901",
"DDInter307"
] | Ibutilide | Castor oil | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
347,
24,
657
]
],
[
[
347,
25,
927
],
[
927,
63,
657
]
],
[
[
347,
40,
540
],
[
540,
24,
657
]
],
[
[
347,
25,
1491
],
[
1491,
2... | [
[
[
"Ibutilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib... | Ibutilide may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Ibutilide (Compound) resembles Dronedarone (Compound) and Dronedarone may cause a moderate interaction that could exacerbate d... |
DB00086 | DB12364 | 1,167 | 1,421 | [
"DDInter1712",
"DDInter200"
] | Streptokinase | Betrixaban | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
1167,
25,
1421
]
],
[
[
1167,
23,
297
],
[
297,
23,
1421
]
],
[
[
1167,
23,
1631
],
[
1631,
62,
1421
]
],
[
[
1167,
24,
992
],
[
992,
... | [
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Streptokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
... | Streptokinase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Streptokinase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause... |
DB00307 | DB00358 | 1,101 | 1,010 | [
"DDInter202",
"DDInter1140"
] | Bexarotene | Mefloquine | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Moderate | 1 | [
[
[
1101,
24,
1010
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
1010
]
],
[
[
1101,
21,
28789
],
[
28789,
60,
1010
]
],
[
[
1101,
24,
392
],
[
39... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mefloquine (Compound)
Bexarotene (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Mefloquine (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00810 | DB01010 | 456 | 61 | [
"DDInter211",
"DDInter622"
] | Biperiden | Edrophonium | A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. | A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. | Moderate | 1 | [
[
[
456,
24,
61
]
],
[
[
456,
63,
1636
],
[
1636,
1,
61
]
],
[
[
456,
24,
1511
],
[
1511,
63,
61
]
],
[
[
456,
63,
1507
],
[
1507,
2... | [
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
[
... | Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine (Compound) resembles Edrophonium (Compound)
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction tha... |
DB00363 | DB12141 | 695 | 971 | [
"DDInter419",
"DDInter817"
] | Clozapine | Gilteritinib | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
695,
25,
971
]
],
[
[
695,
23,
112
],
[
112,
23,
971
]
],
[
[
695,
25,
485
],
[
485,
24,
971
]
],
[
[
695,
25,
823
],
[
823,
63,... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Clozapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Clozapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Clozapine may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may ca... |
DB00836 | DB04844 | 543 | 843 | [
"DDInter1088",
"DDInter1778"
] | Loperamide | Tetrabenazine | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
543,
24,
843
]
],
[
[
543,
24,
479
],
[
479,
40,
843
]
],
[
[
543,
6,
12523
],
[
12523,
45,
843
]
],
[
[
543,
21,
29093
],
[
29093,
... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Loperamide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tetrabenazine (Compound)
Loperamide (Compound) causes Fatigue (Side Effect) and Fatigue... |
DB00687 | DB00991 | 870 | 97 | [
"DDInter747",
"DDInter1358"
] | Fludrocortisone | Oxaprozin | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Moderate | 1 | [
[
[
870,
24,
97
]
],
[
[
870,
63,
362
],
[
362,
1,
97
]
],
[
[
870,
24,
1274
],
[
1274,
24,
97
]
],
[
[
870,
23,
307
],
[
307,
1,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaprozin"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Oxaprozin (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction... |
DB01254 | DB06700 | 1,213 | 643 | [
"DDInter484",
"DDInter511"
] | Dasatinib | Desvenlafaxine | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Moderate | 1 | [
[
[
1213,
24,
643
]
],
[
[
1213,
63,
1100
],
[
1100,
1,
643
]
],
[
[
1213,
6,
8374
],
[
8374,
45,
643
]
],
[
[
1213,
21,
28709
],
[
28709,... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Dasatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Desvenlafaxine (Compound)
Dasatinib (Compound) causes Decreased appetite (Side Effec... |
DB00468 | DB00745 | 1,424 | 307 | [
"DDInter1557",
"DDInter1236"
] | Quinine | Modafinil | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Minor | 0 | [
[
[
1424,
23,
307
]
],
[
[
1424,
25,
1301
],
[
1301,
40,
307
]
],
[
[
1424,
63,
362
],
[
362,
40,
307
]
],
[
[
1424,
24,
1236
],
[
1236,
... | [
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
],
[
"Levacetylmet... | Quinine may lead to a major life threatening interaction when taken with Levacetylmethadol and Levacetylmethadol (Compound) resembles Modafinil (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Modafinil (Compound)
Quinine may... |
DB09020 | DB12141 | 28 | 971 | [
"DDInter212",
"DDInter817"
] | Bisacodyl | Gilteritinib | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
28,
24,
971
]
],
[
[
28,
63,
485
],
[
485,
24,
971
]
],
[
[
28,
24,
730
],
[
730,
63,
971
]
],
[
[
28,
24,
1297
],
[
1297,
24,
... | [
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
... | Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine an... |
DB00601 | DB01001 | 453 | 688 | [
"DDInter1073",
"DDInter1632"
] | Linezolid | Salbutamol | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
453,
24,
688
]
],
[
[
453,
25,
874
],
[
874,
24,
688
]
],
[
[
453,
24,
455
],
[
455,
24,
688
]
],
[
[
453,
64,
1636
],
[
1636,
2... | [
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epinephrine"
],
[
"Epinephrine... | Linezolid may lead to a major life threatening interaction when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause ... |
DB00834 | DB09065 | 932 | 760 | [
"DDInter1215",
"DDInter424"
] | Mifepristone | Cobicistat | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
932,
25,
760
]
],
[
[
932,
62,
1101
],
[
1101,
23,
760
]
],
[
[
932,
25,
1374
],
[
1374,
23,
760
]
],
[
[
932,
63,
723
],
[
723,
... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Mifepristone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarote... | Mifepristone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Mifepristone may lead to a major life threatening interaction when taken with Abiraterone and Abiraterone may caus... |
DB01072 | DB01222 | 915 | 617 | [
"DDInter129",
"DDInter246"
] | Atazanavir | Budesonide | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Major | 2 | [
[
[
915,
25,
617
]
],
[
[
915,
63,
1351
],
[
1351,
1,
617
]
],
[
[
915,
64,
175
],
[
175,
1,
617
]
],
[
[
915,
24,
1220
],
[
1220,
1... | [
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flunisolide"
],
[
"Flunisoli... | Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Flunisolide and Flunisolide (Compound) resembles Budesonide (Compound)
Atazanavir may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Budesonide (Compound)
Atazana... |
DB00344 | DB00572 | 1,302 | 85 | [
"DDInter1543",
"DDInter136"
] | Protriptyline | Atropine | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Moderate | 1 | [
[
[
1302,
24,
85
]
],
[
[
1302,
25,
290
],
[
290,
40,
85
]
],
[
[
1302,
24,
19
],
[
19,
24,
85
]
],
[
[
1302,
63,
1089
],
[
1089,
24... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
]
],
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
],
[
"Cocaine",... | Protriptyline may lead to a major life threatening interaction when taken with Cocaine and Cocaine (Compound) resembles Atropine (Compound)
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate dis... |
DB11979 | DB12095 | 1,320 | 179 | [
"DDInter625",
"DDInter1760"
] | Elagolix | Telotristat ethyl | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
1320,
24,
179
]
],
[
[
1320,
63,
79
],
[
79,
24,
179
]
],
[
[
1320,
24,
214
],
[
214,
24,
179
]
],
[
[
1320,
24,
877
],
[
877,
6... | [
[
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
... | Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fos... |
DB00443 | DB09038 | 251 | 1,450 | [
"DDInter195",
"DDInter636"
] | Betamethasone | Empagliflozin | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
251,
24,
1450
]
],
[
[
251,
40,
1103
],
[
1103,
23,
1450
]
],
[
[
251,
63,
461
],
[
461,
24,
1450
]
],
[
[
251,
23,
659
],
[
659,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause ... | Betamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that coul... |
DB08903 | DB14731 | 996 | 1,518 | [
"DDInter170",
"DDInter1741"
] | Bedaquiline | Tagraxofusp | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by t... | Moderate | 1 | [
[
[
996,
24,
1518
]
],
[
[
996,
63,
1324
],
[
1324,
24,
1518
]
],
[
[
996,
24,
1613
],
[
1613,
24,
1518
]
],
[
[
996,
64,
322
],
[
322,
... | [
[
[
"Bedaquiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Bedaquiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
... | Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon ... |
DB00387 | DB09488 | 1,386 | 103 | [
"DDInter1528",
"DDInter23"
] | Procyclidine | Acrivastine | A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
1386,
24,
103
]
],
[
[
1386,
24,
85
],
[
85,
24,
103
]
],
[
[
1386,
40,
456
],
[
456,
24,
103
]
],
[
[
1386,
63,
999
],
[
999,
2... | [
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[... | Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Procyclidine (Compound) resembles Biperiden (Compound) and Biperiden may cause a moderate interaction that could ... |
DB00029 | DB01105 | 25 | 222 | [
"DDInter99",
"DDInter1665"
] | Anistreplase | Sibutramine | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
25,
24,
222
]
],
[
[
25,
25,
1046
],
[
1046,
63,
222
]
],
[
[
25,
24,
1027
],
[
1027,
24,
222
]
],
[
[
25,
25,
1432
],
[
1432,
2... | [
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
],
[
"Cap... | Anistreplase may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam may... |
DB00703 | DB08882 | 997 | 1,281 | [
"DDInter1167",
"DDInter1070"
] | Methazolamide | Linagliptin | A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
997,
24,
1281
]
],
[
[
997,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
997,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
997,
21,
28762
],
[
28762,
... | [
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
... | Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Methazolamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Methazolamide (Compound) causes Headache (Side Effect) and... |
DB06707 | DB09080 | 584 | 144 | [
"DDInter1060",
"DDInter1331"
] | Levonordefrin | Olodaterol | Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
584,
24,
144
]
],
[
[
584,
63,
1048
],
[
1048,
24,
144
]
],
[
[
584,
64,
1264
],
[
1264,
24,
144
]
],
[
[
584,
1,
817
],
[
817,
... | [
[
[
"Levonordefrin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Levonordefrin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxapram"
],
... | Levonordefrin may cause a moderate interaction that could exacerbate diseases when taken with Doxapram and Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Levonordefrin may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a mo... |
DB09564 | DB13007 | 1,296 | 1,060 | [
"DDInter930",
"DDInter642"
] | Insulin degludec | Enfortumab vedotin | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
1296,
24,
1060
]
],
[
[
1296,
63,
590
],
[
590,
24,
1060
]
],
[
[
1296,
24,
1385
],
[
1385,
63,
1060
]
],
[
[
1296,
24,
433
],
[
433,
... | [
[
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohe... | Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00186 | DB00427 | 905 | 1,233 | [
"DDInter1092",
"DDInter1879"
] | Lorazepam | Triprolidine | Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm. | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Moderate | 1 | [
[
[
905,
24,
1233
]
],
[
[
905,
40,
686
],
[
686,
63,
1233
]
],
[
[
905,
40,
523
],
[
523,
24,
1233
]
],
[
[
905,
24,
104
],
[
104,
... | [
[
[
"Lorazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
]
],
[
[
"Lorazepam",
"{u} (Compound) resembles {v} (Compound)",
"Oxazepam"
],
[
"Oxazepam",
"{u} may cause a moderate in... | Lorazepam (Compound) resembles Oxazepam (Compound) and Oxazepam may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine
Lorazepam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine
Lo... |
DB00902 | DB01409 | 104 | 1,415 | [
"DDInter1168",
"DDInter1815"
] | Methdilazine | Tiotropium | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L... | Moderate | 1 | [
[
[
104,
24,
1415
]
],
[
[
104,
40,
146
],
[
146,
24,
1415
]
],
[
[
104,
63,
1594
],
[
1594,
24,
1415
]
],
[
[
104,
24,
1128
],
[
1128,
... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
],
[
"Propiomazine",
"{u} may cause a... | Methdilazine (Compound) resembles Propiomazine (Compound) and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction th... |
DB00673 | DB00717 | 723 | 1,197 | [
"DDInter112",
"DDInter1312"
] | Aprepitant | Norethisterone | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [no... | Moderate | 1 | [
[
[
723,
24,
1197
]
],
[
[
723,
24,
35
],
[
35,
40,
1197
]
],
[
[
723,
24,
167
],
[
167,
1,
1197
]
],
[
[
723,
63,
989
],
[
989,
1,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norethisterone"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
],
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Quinestrol (Compound) resembles Norethisterone (Compound)
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Norethiste... |
DB08880 | DB09118 | 1,510 | 1,580 | [
"DDInter1771",
"DDInter1711"
] | Teriflunomide | Stiripentol | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
1510,
24,
1580
]
],
[
[
1510,
24,
466
],
[
466,
62,
1580
]
],
[
[
1510,
25,
283
],
[
283,
63,
1580
]
],
[
[
1510,
64,
168
],
[
168,
... | [
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],... | Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Stiripentol
Teriflunomide may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib m... |
DB00661 | DB06605 | 122 | 1,409 | [
"DDInter1928",
"DDInter108"
] | Verapamil | Apixaban | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
122,
24,
1409
]
],
[
[
122,
6,
3486
],
[
3486,
45,
1409
]
],
[
[
122,
21,
28787
],
[
28787,
60,
1409
]
],
[
[
122,
25,
1670
],
[
1670,... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Verapamil",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Verapamil (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Apixaban (Compound)
Verapamil (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Apixaban (Compound)
Verapamil may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a m... |
DB00099 | DB08901 | 440 | 1,468 | [
"DDInter735",
"DDInter1492"
] | Filgrastim | Ponatinib | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
440,
24,
1468
]
],
[
[
440,
24,
478
],
[
478,
24,
1468
]
],
[
[
440,
63,
268
],
[
268,
24,
1468
]
],
[
[
440,
24,
384
],
[
384,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b an... |
DB00973 | DB11718 | 1,149 | 927 | [
"DDInter707",
"DDInter640"
] | Ezetimibe | Encorafenib | Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal vill... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1149,
24,
927
]
],
[
[
1149,
24,
1491
],
[
1491,
24,
927
]
],
[
[
1149,
24,
484
],
[
484,
63,
927
]
],
[
[
1149,
63,
467
],
[
467,
... | [
[
[
"Ezetimibe",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Ezetimibe",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
... | Ezetimibe may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Ezetimibe may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entr... |
DB01166 | DB11986 | 477 | 484 | [
"DDInter379",
"DDInter648"
] | Cilostazol | Entrectinib | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
477,
24,
484
]
],
[
[
477,
62,
1247
],
[
1247,
23,
484
]
],
[
[
477,
63,
222
],
[
222,
23,
484
]
],
[
[
477,
63,
1539
],
[
1539,
... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Cilostazol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine ... |
DB01075 | DB08822 | 1,376 | 911 | [
"DDInter569",
"DDInter156"
] | Diphenhydramine | Azilsartan medoxomil | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in ... | Moderate | 1 | [
[
[
1376,
24,
911
]
],
[
[
1376,
63,
217
],
[
217,
1,
911
]
],
[
[
1376,
21,
29093
],
[
29093,
60,
911
]
],
[
[
1376,
63,
999
],
[
999,
... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olmesar... | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Diphenhydramine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Azilsartan medoxomil (Compound)
Diphenhydramine ma... |
DB00697 | DB01064 | 876 | 1,148 | [
"DDInter1821",
"DDInter987"
] | Tizanidine | Isoprenaline | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Moderate | 1 | [
[
[
876,
24,
1148
]
],
[
[
876,
24,
480
],
[
480,
24,
1148
]
],
[
[
876,
21,
29316
],
[
29316,
60,
1148
]
],
[
[
876,
24,
1151
],
[
1151,
... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
... | Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Tizanidine (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Isoprenaline (Comp... |
DB00197 | DB15328 | 1,324 | 829 | [
"DDInter1881",
"DDInter1896"
] | Troglitazone | Ubrogepant | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Moderate | 1 | [
[
[
1324,
24,
829
]
],
[
[
1324,
24,
1476
],
[
1476,
24,
829
]
],
[
[
1324,
23,
1101
],
[
1101,
24,
829
]
],
[
[
1324,
25,
1510
],
[
1510,... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexa... |
DB00741 | DB14409 | 167 | 1,129 | [
"DDInter885",
"DDInter867"
] | Hydrocortisone | Human adenovirus e serotype 4 strain cl-68578 antigen | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
167,
24,
1129
]
],
[
[
167,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
167,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
167,
1,
251
],
[
251,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}"... | Hydrocortisone may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Hydrocortisone may cause a moderate interaction that could exacerbate diseases w... |
DB00065 | DB00379 | 581 | 143 | [
"DDInter923",
"DDInter1206"
] | Infliximab | Mexiletine | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties. | Moderate | 1 | [
[
[
581,
24,
143
]
],
[
[
581,
25,
980
],
[
980,
63,
143
]
],
[
[
581,
24,
608
],
[
608,
24,
143
]
],
[
[
581,
64,
1057
],
[
1057,
2... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mexiletine"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
],
[
"Tocilizum... | Infliximab may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Mexiletine
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause ... |
DB01069 | DB01619 | 401 | 830 | [
"DDInter1533",
"DDInter1441"
] | Promethazine | Phenindamine | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
401,
24,
830
]
],
[
[
401,
63,
1251
],
[
1251,
1,
830
]
],
[
[
401,
1,
11321
],
[
11321,
40,
830
]
],
[
[
401,
24,
537
],
[
537,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirtazapine"
],
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine and Mirtazapine (Compound) resembles Phenindamine (Compound)
Promethazine (Compound) resembles Metixene (Compound) and Metixene (Compound) resembles Phenindamine (Compound)
Promethazine may cause a moderate interact... |
DB00312 | DB01156 | 1,023 | 593 | [
"DDInter1423",
"DDInter252"
] | Pentobarbital | Bupropion | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
1023,
24,
593
]
],
[
[
1023,
6,
8374
],
[
8374,
45,
593
]
],
[
[
1023,
21,
28952
],
[
28952,
60,
593
]
],
[
[
1023,
23,
752
],
[
752,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Pentobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound)
Pentobarbital (Compound) causes Nightmare (Side Effect) and Nightmare (Side Effect) is caused by Bupropion (Compound)
Pentobarbital may cause a minor interaction that can limit clinical effects when taken with Cimetidine and... |
DB00065 | DB04868 | 581 | 478 | [
"DDInter923",
"DDInter1293"
] | Infliximab | Nilotinib | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
581,
25,
478
]
],
[
[
581,
25,
1468
],
[
1468,
63,
478
]
],
[
[
581,
24,
112
],
[
112,
23,
478
]
],
[
[
581,
24,
10
],
[
10,
24,... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may ... | Infliximab may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cau... |
DB00851 | DB15091 | 611 | 676 | [
"DDInter463",
"DDInter1901"
] | Dacarbazine | Upadacitinib | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
611,
25,
676
]
],
[
[
611,
63,
1461
],
[
1461,
23,
676
]
],
[
[
611,
24,
1430
],
[
1430,
24,
676
]
],
[
[
611,
63,
597
],
[
597,
... | [
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin... | Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipu... |
DB00030 | DB09129 | 1,685 | 625 | [
"DDInter934",
"DDInter373"
] | Insulin human | Chromic chloride | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN). | Moderate | 1 | [
[
[
1685,
24,
625
]
],
[
[
1685,
24,
127
],
[
127,
24,
625
]
],
[
[
1685,
24,
1385
],
[
1385,
63,
625
]
],
[
[
1685,
24,
127
],
[
127,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromic chloride"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
]... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Chromic chloride
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide a... |
DB00717 | DB13928 | 1,197 | 1,385 | [
"DDInter1312",
"DDInter1660"
] | Norethisterone | Semaglutide | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [no... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1197,
24,
1385
]
],
[
[
1197,
25,
1476
],
[
1476,
24,
1385
]
],
[
[
1197,
24,
1144
],
[
1144,
24,
1385
]
],
[
[
1197,
63,
305
],
[
305... | [
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Norethisterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"B... | Norethisterone may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide... |
DB00757 | DB01244 | 1,166 | 762 | [
"DDInter581",
"DDInter192"
] | Dolasetron | Bepridil | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Major | 2 | [
[
[
1166,
25,
762
]
],
[
[
1166,
25,
704
],
[
704,
1,
762
]
],
[
[
1166,
64,
675
],
[
675,
40,
762
]
],
[
[
1166,
6,
12523
],
[
12523,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bepridil"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fentanyl"
],
[
"Fentanyl",
"{u} (Compou... | Dolasetron may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl (Compound) resembles Bepridil (Compound)
Dolasetron may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Bepridil (Compound)
Dolasetron (Compound) ... |
DB00331 | DB00783 | 1,645 | 1,438 | [
"DDInter1164",
"DDInter679"
] | Metformin | Estradiol | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Moderate | 1 | [
[
[
1645,
24,
1438
]
],
[
[
1645,
24,
35
],
[
35,
40,
1438
]
],
[
[
1645,
63,
380
],
[
380,
40,
1438
]
],
[
[
1645,
6,
10659
],
[
10659,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Quinestrol (Compound) resembles Estradiol (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens (Compound) resembles Estra... |
DB00673 | DB14723 | 723 | 159 | [
"DDInter112",
"DDInter1026"
] | Aprepitant | Larotrectinib | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
723,
24,
159
]
],
[
[
723,
23,
222
],
[
222,
23,
159
]
],
[
[
723,
62,
1230
],
[
1230,
23,
159
]
],
[
[
723,
25,
1135
],
[
1135,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
... | Aprepitant may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Citalopram and Citalop... |
DB00490 | DB12332 | 946 | 1,619 | [
"DDInter254",
"DDInter1626"
] | Buspirone | Rucaparib | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
946,
24,
1619
]
],
[
[
946,
25,
222
],
[
222,
23,
1619
]
],
[
[
946,
24,
1213
],
[
1213,
24,
1619
]
],
[
[
946,
24,
159
],
[
159,
... | [
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Buspirone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine"... | Buspirone may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a mod... |
DB00497 | DB09073 | 828 | 951 | [
"DDInter1366",
"DDInter1379"
] | Oxycodone | Palbociclib | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
828,
24,
951
]
],
[
[
828,
24,
1476
],
[
1476,
63,
951
]
],
[
[
828,
24,
259
],
[
259,
24,
951
]
],
[
[
828,
25,
283
],
[
283,
6... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonac... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.